Molecular mechanism of action of selective estrogen receptor modulator in target tissues

Endocrine Journal

Volumn 52, Issue 2, 2005, Pages 161-167

  Ohmichi, Masahide ^a   Tasaka, Keiichi ^a   Kurachi, Hirohisa ^b   Murata, Yuji ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b YAMAGATA UNIVERSITY   (Japan)

Author keywords

Alzheimer's disease; Breast cancer; Selective estrogen receptor modulator; Vascular endothelial cells; Vascular smooth muscle cells

Indexed keywords

AMYLOID BETA PROTEIN; ESTROGEN; ESTROGEN RECEPTOR; PROTEIN KINASE B; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TELOMERASE;

ALZHEIMER DISEASE; BREAST CANCER; CARDIOVASCULAR RISK; DRUG ACTIVITY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; REVIEW; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BLOOD VESSELS; BRAIN; CELL DIVISION; ENDOTHELIAL CELLS; FEMALE; HUMANS; MALE; MAMMARY GLANDS, HUMAN; MUSCLE, SMOOTH, VASCULAR; ORGAN SPECIFICITY; PHOSPHORYLATION; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TELOMERASE;

EID: 19744365947     PISSN: 09188959     EISSN: None     Source Type: Journal    
DOI: 10.1507/endocrj.52.161     Document Type: Review

References (57)

1. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH (1991) Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med 325: 756-762.
2. Mendelsohn ME, Karas RH (1999) Mechanisms of disease: The protective effects of estrogen on the cardiovascular system. N Engl J Med 340: 1801-1811.
3. Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
4. Women's Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712.
5. Oishi A, Ohmichi M, Takahashi K, Takahashi T, Mori-Abe A, Kawagoe J, Otsu R, Mochizuki Y, Inaba N, Kurachi H (2004) Medroxyprogesterone acetate attenuates estrogen-induced nitric oxide production in human umbilical vein endothelial cells. Biochem Biophys Res Commun 324: 193-198.
6. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen, C (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337: 1641-1647.
7. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, Shah AS, Anderson PW (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279: 1445-1451.
8. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281: 2189-2197.
9. Mendelsohn ME, Karas RH (1994) Estrogen and the blood vessel wall. Cur Opin Cardiol 9: 619-626.
10. Farhat MY, Lavigne MC, Ramwell PW (1996) The vascular protective effects of estrogen. FASEB J 10: 615-624.
11. Lantin-Hermoso RL, Rosenfeld CR, Yuhanna IS, German Z, Chen Z, Shaul PW (1997) Estrogen acutely stimulates nitric oxide synthase activity in fetal pulmonary artery endothelium. Am J Physiol 273: 119-126.
12. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, Shaul PW (1999) Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 103: 401-406.
13. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, Jo I (1999) Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor alpha localized in caveolae. Biochem Biophys Res Commun 263: 257-262.
14. Franke TF, Kaplan DR, Cantley LC (1997) PI3K: downstream AKTion blocks apoptosis. Cell 88: 435-437.
15. Dudek H, Datta SR, Franke TF, Birnbaum MJ, Yao R, Cooper GM, Segal RA, Kaplan DR, Greenberg ME (1997) Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 275: 661-665.
16. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, Evan G (1997) Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 385: 544-548.
17. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Papapetropoulos A, Sessa WC (1999) Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597-601.
18. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399: 601-605.
19. Hisamoto K, Ohmichi M, Kurachi H, Hayakawa J, Kanda Y, Nishio Y, Adachi K, Tasaka K, Miyoshi E, Fujiwara N, Taniguchi N, Murata Y (2001) Estrogen induces the Akt-dependent activation of endothelial nitric-oxide synthase in vascular endothelial cells. J Biol Chem 276: 3459-3467.
20. Ohmichi M, Kanda Y, Hisamoto K, Morishige K, Takahashi K, Sawada K, Minekawa R, Tasaka K, Murata Y (2003) Rapid changes of flow-mediated dilatation after surgical menopause. Maturitas 44: 125-131.
21. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK (2000) Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407: 538-541.
22. Figtree GA, Lu Y, Webb CM, Collins P (1999) Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100: 1095-1101.
23. Simoncini T, Genazzani AR (2000) Raloxifene acutely stimulates nitric oxide release from human endothelial cells via an activation of endothelial nitric oxide synthase. J Clin Endocrinol Metab 85: 2966-2969.
24. Gradishar WJ, Jordan VC (1997) Clinical potential of new antiestrogens. J Clin Oncol 15: 840-852.
25. Hisamoto K, Ohmichi M, Kanda Y, Adachi K, Nishio Y, Hayakawa J, Mabuchi S, Takahashi K, Tasaka K, Miyamoto Y, Taniguchi N, Murata Y (2001) Induction of endothelial nitric-oxide synthase phosphorylation by the raloxifene analog LY117018 is differentially mediated by Akt and extracellular signal-regulated protein kinase in vascular endothelial cells. J Biol Chem 276: 47642-47649.
26. Simoncini T, Genazzani AR, Liao JK (2002) Nongenomic mechanisms of endothelial nitric oxide synthase activation by the selective estrogen receptor modulator raloxifene. Circulation 105: 1368-1373.
27. Simoncini T, Varone G, Fornari L, Mannella P, Luisi M, Labrie F, Genazzani AR (2002) Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 143: 2052-2061.
28. Braun-Dullaeus RC, Mann MJ, Dzau VJ (1998) Cell cycle progression: new therapeutic target for vascular proliferative disease. Circulation 98: 82-89.
29. Schwartz SM, deBlois D, O'Brien ER (1995) The intima: soil for atherosclerosis and restenosis. Circ Res 77: 445-465.
30. Hanke H (1996) Proliferative response of smooth muscle cells after experimental balloon angioplasty. Circulation 93: 202.
31. Ross R (1995) Cell biology of atherosclerosis. Ann Rev Physiol 57: 791-804.
32. Kindy MS, Sonenshein GE (1986) Regulation of oncogene expression in cultured aortic smooth muscle cells. Post-transcriptional control of c-myc mRNA. J Biol Chem 261: 12865-12868.
33. Nilsson J, Sjolund M, Palmberg L, Thyberg J, Heldin CH (1985) Arterial smooth muscle cells in primary culture produce a platelet-derived growth factor-like protein. Proc Natl Acad Sci USA 82: 4418-4422.
34. Sullivan TR Jr, Karas RH, Aronovitz M, Faller GT, Ziar JP, Smith JJ, O'Donnell TF Jr, Mendelsohn ME (1995) Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 96: 2482-2488.
35. Ross R (1986) The pathogenesis of atherosclerosis - an update. N Engl J Med 314: 488-500.
36. Kolodgie FD, Jacob A, Wilson PS, Carlson GC, Farb A, Verma A, Virmani R (1996) Estradiol attenuates directed migration of vascular smooth muscle cells in vitro. Am J Pathol 48: 969-976.
37. Somjen D, Kohen F, Jaffe A, Amir-Zaltsman A, Knoll E, Stern N (1998) Effects of gonadal steroids and their antagonists on DNA synthesis in human vascular cells. Hypertension 32: 39-45.
38. Takahashi K, Ohmichi M, Yoshida M, Hisamoto K, Mabuchi S, Arimoto-Ishida E, Mori A, Tsutsumi S, Tasaka K, Murata Y, Kurachi H (2003) Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 178: 319-329.
39. Foster JS, Wimalasena J (1996) Estrogen regulates activity of cyclin-dependent kinases and retinoblastoma protein phosphorylation in breast cancer cells. Mol Endocrinol 10: 488-498.
40. Gewirtz DA, Di YM, Randolph JK, Jain PT, Valerie K, Bullock S, Nath N, Chellappan SP (2001) Rb dephosphorylation and suppression of E2F activity in human breast tumor cells exposed to a pharmacological concentration of estradiol. Arch Biochem Biophys 388: 243-252.
41. Mori-Abe A, Tsutsumi S, Takahashi K, Toya M, Yoshida M, Du B, Kawagoe J, Nakahara K, Takahashi T, Ohmichi M, Kurachi H (2003) Estrogen and raloxifene induce apoptosis by activating p38 mitogen-activated protein kinase cascade in synthetic vascular smooth muscle cells. J Endocrinol 178: 417-426.
42. Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352: 98-101.
43. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle P (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352: 93-97.
44. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, Boyle P (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361: 296-300.
45. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65, 125-134.
46. Kawagoe J, Ohmichi M, Takahashi T, Ohshima C, Mabuchi S, Takahashi K, Igarashi H, Mori-Abe A, Saitoh M, Du B, Ohta T, Kimura A, Kyo S, Inoue M, Kurachi H (2003) Raloxifene inhibits estrogen-induced up-regulation of telomerase activity in a human breast cancer cell line. J Biol Chem 278: 43363-43372.
47. Fernando RI, Wimalasena J (2004) Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15: 3266-3284.
48. Gaben AM, Saucier C, Bedin M, Redeuilh G, Mester J (2004) Mitogenic activity of estrogens in human breast cancer cells does not rely on direct induction of mitogen-activated protein kinase/extracellularly regulated kinase or phosphatidylinositol 3-kinase. Mol Endocrinol 18: 2700-2713.
49. Bondi MW, Salmon DP, Monsch AU, Galasko D, Butters N, Klauber MR, Thal LJ, Saitoh T (1995) Episodic memory changes are associated with the APOE-epsilon 4 allele in nondemented older adults. Neurology 45: 2203-2206.
50. Miech RA, Breitner JC, Zandi PP, Khachaturian AS, Anthony JC, Mayer L (2002) Incidence of AD may decline in the early 90s for men, later for women: The Cache County study. Neurology 58: 209-218.
51. Zandi PP, Carlson MC, Plassman BL, Welsh-Bohmer KA, Mayer LS, Steffens DC, Breitner JC, Cache County Memory Study Investigators (2002) Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County Study. JAMA 288: 2123-2129.
52. Tang MX, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R (1996) Effect of oestrogen during menopause on risk and age at onset of Alzheimer's disease. Lancet 348: 429-432.
53. Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter E (1997) A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: the Baltimore Longitudinal Study of Aging. Neurology 48: 1517-1521.
54. Paganini-Hill A, Henderson VW (1996) Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 156: 2213-2217.
55. Skoog I, Gustafson D (1999) HRT and dementia. J Epidemiol Biostat 4: 227-251.
56. Du B, Ohmichi M, Takahashi K, Kawagoe J, Ohshima C, Igarashi H, Mori-Abe A, Saitoh M, Ohta T, Ohishi A, Doshida M, Tezuka N, Takahashi T, Kurachi H (2004) Both estrogen and raloxifene protect against β-amyloid-induced neurotoxicity in estrogen receptor α-transfected PC12 cells by activation of telomerase activity via Akt cascade. J Endocrinol 183: 605-615.
57. Shang Y, Brown M (2002) Molecular determinants for the tissue specificity of SERMs. Science 295: 2465-2468.